The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Selozok     butanedioic acid; 1-[4-(2...

Synonyms: Toprol XL, Spesicor Dos, Seloken ZOC, Beloc- Zok, SureCN40916, ...
This record was replaced with 4171.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of metoprolol


High impact information on metoprolol

  • OBJECTIVE: To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure [5].
  • Monotherapy with ER metoprolol succinate induced dose-related reductions in sitting systolic/diastolic BP (DBP) (mean 8.1/7.7 to 9.7/11.1 mm Hg) as did ER felodipine (mean 7.7/7.7 to 14.0/11.8) and the combinations reflected additive effects (mean 13.8/11.0 to 19.8/15.2) [2].
  • A prototype formulation of metoprolol succinate using this technology was developed and the drug release from the formulation was adjusted to have a release profile which would match the circadian rhythm i.e. a higher amount of drug would be available after an initial lower release (accelerated type of release) [6].
  • Carvedilol and extended-release metoprolol succinate are 2 beta-blockers currently approved in the United States for the treatment of patients with heart failure [7].
  • The increase in left ventricular ejection fraction measure at baseline and 6 months measured by radioisotopic ventriculography was greater in the metoprolol succinate group (27. 5% to 36.3%) than in the placebo group (26% to 27.9%) (P <.015) [3].

Chemical compound and disease context of metoprolol


Biological context of metoprolol


Associations of metoprolol with other chemical compounds


Gene context of metoprolol

  • The objective of this study was to determine whether 3 months of treatment with extended-release metoprolol succinate would reduce C-reactive protein (CRP) levels [15].

Analytical, diagnostic and therapeutic context of metoprolol


  1. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Thornley-Brown, D., Wang, X., Wright, J.T., Randall, O.S., Miller, E.R., Lash, J.P., Gassman, J., Contreras, G., Appel, L.J., Agodoa, L.Y., Cheek, D. Arch. Intern. Med. (2006) [Pubmed]
  2. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Frishman, W.H., Hainer, J.W., Sugg, J. Am. J. Hypertens. (2006) [Pubmed]
  3. Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Goldstein, S., Kennedy, H.L., Hall, C., Anderson, J.L., Gheorghiade, M., Gottlieb, S., Jessup, M., Karlsberg, R.P., Friday, G., Haskell, L. Am. Heart J. (1999) [Pubmed]
  4. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. Nikolaidis, L.A., Poornima, I., Parikh, P., Magovern, M., Shen, Y.T., Shannon, R.P. J. Am. Coll. Cardiol. (2006) [Pubmed]
  5. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., Halinen, M., Dietz, R., Neuhaus, K.L., Jánosi, A., Thorgeirsson, G., Dunselman, P.H., Gullestad, L., Kuch, J., Herlitz, J., Rickenbacher, P., Ball, S., Gottlieb, S., Deedwania, P. JAMA (2000) [Pubmed]
  6. Modulated release metoprolol succinate formulation based on ionic interactions: in vivo proof of concept. Ravishankar, H., Patil, P., Samel, A., Petereit, H.U., Lizio, R., Iyer-Chavan, J. Journal of controlled release : official journal of the Controlled Release Society. (2006) [Pubmed]
  7. Beta-blockers in chronic heart failure: considerations for selecting an agent. Kukin, M.L. Mayo Clin. Proc. (2002) [Pubmed]
  8. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. Batisky, D.L., Sorof, J.M., Sugg, J., Llewellyn, M., Klibaner, M., Hainer, J.W., Portman, R.J., Falkner, B. J. Pediatr. (2007) [Pubmed]
  9. Aortic aneurysm and electroconvulsive therapy in elderly depressive patient. Caliyurt, O., Tuglu, C., Vardar, E. The journal of ECT. (2003) [Pubmed]
  10. Achieving optimal beta1-blockade with metoprolol CR/Zok. Wikstrand, J. Basic Res. Cardiol. (2000) [Pubmed]
  11. Extended-release metoprolol succinate in chronic heart failure. Tangeman, H.J., Patterson, J.H. The Annals of pharmacotherapy. (2003) [Pubmed]
  12. Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. Falkner, B., Francos, G., Kushner, H. Journal of clinical hypertension (Greenwich, Conn.) (2006) [Pubmed]
  13. Heart Failure and Its Management With beta-Blockade: Potential Applications of Once-Daily Therapy. Yancy, C.W. Journal of clinical hypertension (Greenwich, Conn.) (2007) [Pubmed]
  14. Refined anaesthesia for implantation of engineered experimental aortic valves in the pulmonary artery using a right heart bypass in sheep. Schauvliege, S., Narine, K., Bouchez, S., Desmet, D., Van Parys, V., Van Nooten, G., Gasthuys, F. Lab. Anim. (2006) [Pubmed]
  15. The effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. King, D.E., Egan, B.M., Mainous, A.G., Geesey, M.E. Journal of clinical hypertension (Greenwich, Conn.) (2006) [Pubmed]
  16. Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions. Atar, I., Korkmaz, M.E., Atar, I.A., Gulmez, O., Ozin, B., Bozbas, H., Erol, T., Aydinalp, A., Yildirir, A., Yucel, M., Muderrisoglu, H. Eur. Heart J. (2006) [Pubmed]
  17. Beta1-adrenoceptor blockade mitigates excessive norepinephrine release into cardiac interstitium in mitral regurgitation in dog. Hankes, G.H., Ardell, J.L., Tallaj, J., Wei, C.C., Aban, I., Holland, M., Rynders, P., Dillon, R., Cardinal, R., Hoover, D.B., Armour, J.A., Husain, A., Dell'Italia, L.J. Am. J. Physiol. Heart Circ. Physiol. (2006) [Pubmed]
  18. How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Wikstrand, J., Wedel, H., Ghali, J., Deedwania, P., Fagerberg, B., Goldstein, S., Gottlieb, S., Hjalmarson, A., Kjekshus, J., Waagstein, F. Cardiac electrophysiology review. (2003) [Pubmed]
  19. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Kindermann, M., Maack, C., Schaller, S., Finkler, N., Schmidt, K.I., Läer, S., Wuttke, H., Schäfers, H.J., Böhm, M. Circulation (2004) [Pubmed]
  20. Beta-blockers in heart failure: are pharmacological differences clinically important? Metra, M., Cas, L.D., di Lenarda, A., Poole-Wilson, P. Heart failure reviews. (2004) [Pubmed]
WikiGenes - Universities